Exhibit 99.1
1 AMITIZA Intellectual Property •AMITIZA has a robust patent estate –Latest patents expire in 2027 •Paragraph IV certification notice letter to Sucampo received on January 2, 2013 regarding ANDA submitted to FDA by Anchen Pharmaceuticals and Par Pharmaceuticals –Notice letter alleges AMITIZA’s composition, method of use, and/or formulation patents are invalid, unenforceable, and/or will not be infringed by Anchen’s manufacture, use or sale of the product described in its ANDA. •On February 8 Sucampo announced it had filed a patent infringement lawsuit against Anchen and Par Pharmaceuticals –Sucampo is joined by Takeda and R-Tech Ueno in the lawsuit Under Hatch-Waxman Act, patent infringement lawsuit will stay FDA approval of Anchen’s ANDA for up to 30 months from receipt of Jan 2 ’13 Notice letter 2 RESCULA US Launch Overview •sNDA approved December 2012 –RESCULA may be used as a first-line agent or concomitantly with other topical ophthalmic drug products to lower intraocular pressure –RESCULA is a BK (Big Potassium) channel activator, which is different from other intraocular pressure (IOP) lowering agents. –RESCULA is believed to reduce elevated IOP by increasing the outflow of aqueous humor through the trabecular meshwork •RESCULA launch in US Q1 2013 –40 specialty reps –Product has been shipped to pharmacies and wholesale agreements are in place –We will begin filling scripts in late February with WAC price of $99 –Heavy sampling to facilitate patient trial 3 Trading Symbol SCMP (NASDAQ) Corporate Headquarters Bethesda, MD Stock Price (02-07-2013), 52-Week Range $5.22, $8.50 to $3.78 Shares Outstanding (9-30-2012) 41.9 M (1 class of common stock) Daily Volume (90-day average) 105,422 Market Capitalization (02-07-2013) $219.1 M Debt (9-30-12) $61.2 M Cash & Equivalents (9-30-12) $82.1 M Enterprise Value (02-07-2013) $198.1 M YTD Total Revenue (9-30-2012) $46.6 M Full-time Employees (02-08-2013) 123 Fiscal Year Ends December 31 Accounting Firm PricewaterhouseCoopers, LLP Key Facts
